This resulted in an increase in CD4+ and CD8+ to 4PD-1hi ratios in the cryoablation plus ipilimumab plus nivolumab cohort at all time points and in the UC and melanoma cohorts at later time points (e.g., 6 weeks post-treatment [PS]). The gene discussed is CD8A; the disease is melanoma.